GUFIC BIOSCIENCES LIMITED

Regd office: 2nd Floor, Building A, Moti Baug, 118/119, S.V.Road, Andheri(Wost), Mumbal-400 058

UNAUDITED FINANCIAL (PROVISIONAL) RESULTS FOR THE QUARTER ENDED 31.12.2012

	Quarter	<u> </u>					For the
Basilesian , in the second	Ended	£		<b>.</b>		Period Ended	
Particulars — · — — — — — — —	31.12.2012		E	31.12.2011		f	31.03.2012
INCOME:	Unaudited	Unaudited	Unauditod	Unaudited	Unaudiled	Unaudited	Audited
Net Sales / Income from Operations (Net of Excise	1						
Drith) Drith)	2454 77	2270 24	2244.04	2,000			
Other Operating Income	2461.77	1					• • • • • • • • • • • • • • • • • • • •
	14.77						
Total Income from Operations (Net)	2476.54	2375.20	2723.12	2198.61	7574.86	6185.70	8381.0
EXPENSES:		<b>.</b>		i			
Cost of Materials Consumed	965.71					2	1
Purchase of Stock-in-Trade	3\$5.15	373.10	423,46	596.45	1151.73	1379,45	1953.3
Changes in Inventories of Finished Goods, Work-in-	2000 BAN						]
Progress and Stock-in-Trade	(57.38)			, , , ,		7	· ·
Employee Benefits Expenses	130.20	· ·					•
Depreciation and Amortisation Expenses	50.99			_			
Other Expesses	810.25						<u> </u>
Total Exponses	2254.92	2160.84	2525.83	2085.80	6941.59	\$786.13	7833.2
Profit from Operations before Other Income.		<u> </u>					
finance costs and Exceptional Itoms	221.62	B	<b>3</b>	112.81	633.27	399.57	547.8
Other Income	3.13	0.48	0.15	2.44	3.76	3.18	12.2
Profit from ordinary activities before finance							
costs and exceptional items	224.75	214.83	197,45	115.25	537.03	402.75	560.0
Finance Costs	94.25				•	1	
Profit from ordinary activities after finance costs			<del></del>	<u> </u>			
but before exceptional items	130,49	136.11	134,84	62.87	401,44	224.12	297.0
Exceptional Items	0.00	_				_	
Profit from Ordinary Activities Before Tax	130.49				<u> </u>		
ax Expenses	45.40		1	·		•	1
· ·				<u> </u>			
Net Profit from Ordinary Activities After Tax Extraordinary Items (Net of Tax Expenses)	85.09	•					
•	0.00						
Net Profit for the Period	85.09	88.86	87.59	38.65	261.54	142,90	152.7
		1					
Paid up Equity Share Capital (Face Value of Rs 1 /-		<u> </u>	t ·	)			
Each)	773,50	, , ,	773.50	773.50	773.50	773.50	773.5
Reserves Excluding Revaluation Reserves	1439.46	1354.39	1265.57	1213.06	1439,46	1213.06	1177.5
· ·				ľ	}		
E.P.S	0.11	0.11	0.11	D.05	0.34	0.18	0.2
	1	}	,				
Public Shareholding		•	<u> </u>				
- Number of Shares of Rs 1 /- Each	23222355	23222355	23322337	23322337	- 23222355	23322337	2332233
Percentage of shareholding	30.02%	30.02%	30.15%	30.15%			
•			Ì	i			
Promoters and Promoter group Shareholding			<b>§</b>	1			
a) Piedgod / Encumbored	1						
Number of Shares of Rs 1 /- Each	Ð	C	. 0	a	o	a	
Percentage of Shares the total Shareholding	•	<b>‡</b>	1	1			
of Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00
Percentage of Sharesholding on total	]	1			0.00		9.00
Capital of the company	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00
	-,,,,,,	]	1	J. 44 /8	4.04 M	V.VU 78	ψ.υψ.
b) Non - Encumbered	1	1		1			
- Number of Shares of Rs 1 /- Each	54127645	54127645	54027663	54027663	54127645	51077000	£100701
- Percentage of Shares the total Shareholding			1 04051489	2021003	14 12 ( 143	54027663	5402768
of Promoter and Promoter group	100.00%	100.00%	100.00%	400 000	400.00=/	466 664	400
Percentage of Sharesholding on total		]	100.9974	100.00%	100.00%	103.00%	100.00
Capital of the company	69.98%	20 00ss	CA APPL				,
Committee of the fortification	98.30%	69.98%	69,85%	69.85%	69.98%	69.85%	69.85

The above Results were reviewed by the Audil Committee and taken on record by the Board of Directors at its meeting held on 14th February, 2013 and a limited review of the same has been carried out by the Statutory Auditors of the Company.

Place: Mumbal Date: 14.02.2013 For GUFIC BIOSCIENCES LID.

Praner & Choksi Ex. Director GUFIC BIOSCIENCES LIMITED

Regd office: 2nd Floor, Building A. Moti Baug, 118/119, S.V.Road, Andheri(West), Mumbal-400 058

UNAUDITED (PROVISIONAL) SEGMEN		Quarter	Quarter	Quarter	For-the-	For the	For the
Particulars	Ended -		Ended	Ended		Period Ended	
The state of the s	31.12.2012			31.12.2011	31.12.2012	1	31.03.2012
		1	Unaudited	Unaudited	Unaudited		Audited
SEGMENT REVENUE							· · · · · · · · · · · · · · · · · · ·
Sales & Service		1		1		•	ļ
Pharma	2239.04	2161.06	2403 16	2015.81	6803.26	5690 12	7670.26
Consumer	222.73	209.25	310.85	179.53	742,83	485.43	670.90
Total	2461.77	2370.31	2714.01	2196.34	7546.09	6176.55	8341.16
Unallocabet Income	17.9G	5.36	9.27	4.71	32.53	12.33	52 12
Fotal Segment Revenue	2479.67	2375.67	2723.28	2201.05	7578.62	6188.88	8393.28
SEGMENT RESULTS	<u> </u>					<u> </u>	
Phams	434,13	419.01	465.95	390.45	1319.09	1085.22	1487.19
Consumer	43 08	40.48	J				129.78
TOTAL.	477.21	459.49	526.09			A CONTRACTOR OF THE PARTY OF TH	1616.97
Less: Unallocated over heads	201.47		277.63				•
Finance Charges	94.25	_	4				263.07
Depreciation	50.99	51.64	51.00		1	150.00	188 12
Tax provision	45.40		<b>1</b>			· ·	
Net Profit after Tax	85.09			<u> </u>		<u> </u>	

The above Results were reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 14th February, 2013 and a limited review of the same has been carried out by the Statutory Auditors of the Company.

2> Investors Complaints received and disposed off during the Quarter Ended 31st December, 2012.

Complaints Pending at the Beginning of the quarter

Ni

Nos

Complaints received during the quarter Disposal of Complaints

3

Complaints lying unresolved at the end of the quarter

3

FOR GUFIC BIOSCIENCES LTP.

Pramay J Choksi Ex. Director

Date: 14.02.2013 Place: Mumbai

<sup>3&</sup>gt; Previous periods' figures have been regrouped, rearranged, reworked or reclassified wherever necessary to confirm to the current periods' classification